Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Investor Presentation (May 2026)
37 slides from Imricor Medical Systems's investor presentation, May 4, 2026
Slide 1: Equity Raising Presentation
Equity Raising Presentation May 2026 For personal use only Turning regulatory and clinical momentum into commercial scale Imricor's vision is to bring iCMR to every cardiac centre in the world IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Imricor Medical Systems, Inc. (IMR or Imricor) in connection with IMR’s not historical facts), including but not limited to, statements related to IMR’s financial performance, business strategy proposed capital raising (the Capital Raise), comprising
Slide 3: Disclaimer
Disclaimer Financial information statements made by the Joint Lead Managers, their advisers, or any of their respective Beneficiaries in relation to the Capital Raise. You further expressly disclaim that you are in a fiduciary relationship with any of IMR, the Joint Lead Investors should note that t
Slide 4: Executive Summary
Executive Summary For personal use only • Imricor (IMR or the Company) is the global leader in the design and development of MRI compatible interventional medical devices. The Company has dedicated 20 years to building an entire ecosystem of capital equipment, consumable devices and software to enab
Slide 5: Executive Summary: Key outcomes of Equity Raising
Executive Summary For personal use only • Successful completion of the Offer will provide the Company with a cash runway extending into 2028, enabling the Company to: • Establish an installed base of NorthStar customers among U.S. based Pediatric Hospitals during CY2026; • Secure the regulatory appr
Slide 6: Imricor is bringing MRI into X-Ray based cath labs
Imricor is bringing MRI into X-Ray based cath labs From inferring To visualizing For personal use only • Radiation exposure • No radiation • Lead protection required • No lead protection • Point by point mapping • Soft tissue visible in exquisite detail • Additional devices and costs • Maps generate
Slide 7: Imricor's solution – adding value to all stakeholders
Imricor’s solution – adding value to all stakeholders For personal use only Patient Doctor Hospital Payer • Higher single procedure success rates • Improved visualisation of heart • Similar cost to set up an iCMR EP lab • Similar or lower per-procedure costs achieved in clinical trials for AFL anato
Slide 8: Attractive business model - capital sales + high margin recurring revenue
Attractive business model - capital sales + high margin recurring revenue For personal use only MRI compatible equipment Vendor Revenue type Ablation catheter Imricor Consumable Diagnostic catheter Imricor Consumable Transseptal puncture kit Imricor Consumable Dispersive electrode Imricor Consumable
Slide 9: Regulatory process is gaining momentum
Regulatory process is gaining momentum Geography Regulation Imricor Product Suite Pathway Status Details • NorthStar For personal use only • Advantage-MR EP Recorder/Stimulator • Vision-MR Diagnostic Catheter 2.0 Med • Vision-MR Diagnostic Cable Full technology platform to perform real-time Europe D
Slide 10: iCMR Lab Economics - Hospital
iCMR Lab Economics - Hospital better outcomes, higher throughput, higher margins For personal use only US Top 50 Hospitals by volume AFL VT Afib Total Average procedures pa 434 173 1010 1617 Imricor estimated ASP US$ per procedure $4000 $6500 $6500 Revenue opportunity per hospital for Imricor $1.7m
Slide 11: iCMR Lab Economics: Imricor
iCMR Lab Economics : Imricor For personal use only Each new lab installation generates US$500k-US$700k of capital revenue Total Potential Revenue ATRIAL FLUTTER VT AFIB per Hospital Procedures: 100 +/- Procedures: 100 +/- Procedures: 300 +/- Procedures: 500* +/- ASP : US$4000 ASP : US$6500 ASP : US$
Slide 12: Delivering key milestones in 2025
Delivering key milestones in 2025 Regulatory & Clinical Commercial Financial For personal use only • CE Mark approval under MDR for 2nd generation • Completed integration and testing of NorthStar on • FY25 revenue of US$292k temporarily impacted by ablation catheter and capital equipment Philips MRI
Slide 13: Looking ahead to 2026 & beyond
Looking ahead to 2026 & beyond For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 14: Board of directors strengthened to support growth and commercialisation
Board of directors strengthened to support growth and commercialisation For personal use only “Throughout my 30-year career at companies such as Medtronic and Johnson & Johnson MedTech, I have witnessed remarkable innovations that have reshaped the landscape of healthcare and improved millions of li
Slide 15: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers For personal use only Drivers of global catheter ablation market Electrophysiology Device Market (US$bn) 70 59.8 60 Increased incidence of cardiac disea
Slide 16: Pipeline benefiting from investment in sales
Pipeline benefiting from investment in sales European active pipeline is rebuilding For personal use only Imricor’s products are currently approved in 31 countries, with 8 45 countries containing customer sites 40 Estimated over 1,500,000 ablation 35 procedures across the US, EU and Aus in 30 2026,
Slide 17: NorthStar – Cleared and ready for commercialisation
NorthStar – Cleared and ready for commercialisation NorthStar Key piece of the infrastructure, intended to be the For personal use only central hub of every iCMR lab Mapping System AI powered application potential well beyond cardiac ablation Strong in-bound interest from hospitals Solves problem fo
Slide 18: Several key value drivers during 2025/26
Several key value drivers during 2025/26 FDA Approval for US commercial release of New site activations, growing installed base For personal use only platform technology globally • 510(k) submissions / approvals • VISABL-AFL clinical trial expands in U.S. • PMA submissions / approvals Middle East fi
Slide 19: Equity Raising Summary
Equity Raising Summary For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 20: Equity Raising Summary
Equity Raising Summary ▪ Imricor is seeking to raise approximately A$60.0 million via a single tranche institutional placement (Placement) ▪ Approximately 32.4 million new fully paid CHESS Depositary Interests (New CDIs) to be issued utilising the Company’s available placement capacity For personal
Slide 21: Sources and Use of Funds
Sources and Use of Funds Sources of Funds A$m % Post completion of the Placement, IMR will have pro-forma cash balance of For personal use only US$74m / A$108m* Placement proceeds 60.0 100.0% Total sources 60.0 100.0% • The proceeds will be used launch NorthStar in the U.S. including into Children’s
Slide 22: Equity Raising Timetable
Equity Raising Timetable For personal use only Event Date Trading halt and launch of Placement 30 April 2026 Announcement of completion of Placement and trading halt lifted 4 May 2026 Settlement of New Securities issued under the Placement 7 May 2026 Allotment, quotation and trading of New Securitie
Slide 23: Questions?
Questions? For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 24: Appendix – Additional Information
Appendix 1 – Additional Information For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 25: VISABL-AFL Clinical Trial Sites
VISABL-AFL Clinical Trial Sites DR. AV KOLANDAIVELU DR. AJAY PILLAI DR. MARCO GÖTTE PROF. JUERG SCHWITTER Johns Hopkins University Virginia Commonwealth University Health Amsterdam University Medical Center MD, Director Cardiac MR Centre, For personal use only University Hospital Lausanne (CHUV) “MR
Slide 26: A strong intellectual property portfolio
A strong intellectual property portfolio For personal use only Imricor’s patents protect technology that allows Imricor to manufacture medical devices that are uniquely MRI compatible. Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat behind Imricor. 21 is
Slide 27: Imricor Leadership: Management
Imricor Leadership: Management STEVE WEDAN GREG ENGLEHARDT NICK TWOHY JENNIFER WEISZ VIC FABANO For personal use only President and Chief Executive Vice President of Global Sales Vice President of Marketing Vice President of Regulatory and Vice President of Operations Officer, and Board Chair and Bu
Slide 28: Imricor Leadership: Board of directors
Imricor Leadership: Board of directors For personal use only STEVE WEDAN MARK TIBBLES PETER MCGREGOR ANITA MESSAL JEFFREY LEIGHTON ALDO DENTI President and Chief Executive Deputy Chair and Lead Non-executive Director Non-executive Director Non-executive Director Non-executive Director Officer, and B
Slide 29: Key terms
Key terms • Medical device developed by Imricor, designed for use within an MRI Vision-MR Ablation Catheter • World first, no competitors, all others only compatible with X-ray • Irregular heartbeat, affects approximately 2% of US population For personal use only • Expected to double to 4% of US pop
Slide 30: Appendix – Risk Factors
Appendix 2 – Risk Factors For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 31: Risk Factors
Risk Factors Please see Imricor’s ASX Announcement “Form 10 Registration with the U.S. Securities and Exchange Commission” dated 19 March 2026, and the Ammendment to Form 10 dated 28 April 2026 for a complete list of Risk Factors included in the Form 10. Regulatory: Imricor will, subject to regulato
Slide 32: Risk Factors
Risk Factors Intellectual Property Rights: The protection of the intellectual property relied upon by Imricor is critical to its business and commercial success. If Imricor is unable to protect or enforce the intellectual property rights embodied in its products, there is a risk that other companies
Slide 33: Risk Factors
Risk Factors The costs and management time involved in complying with Delaware laws, Australian laws and U.S. reporting requirements are likely to be significant: Imricor has lodged a Form 10 and and Amendment to Form 10 with the Securities and Exchange Commission (SEC) and will shortly become a U.S
Slide 34: Appendix – International Selling Restrictions
Appendix 4 – International Selling Restrictions For personal use only IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 35: International Selling Restrictions
International Selling Restrictions This document does not constitute an offer of CDIs in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the CDIs may not be offered or sold, in any country outside Australia except to the extent p
Slide 36: International Selling Restrictions
International Selling Restrictions Singapore This document and any other materials relating to the CDIs have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in connec
Slide 37: Contact information
Contact information Investors & Australian Media: For personal use only Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Nick Corkill Vice President, Corporate Strategy Email: nick.c
Imricor Medical Systems — Investor Presentation (May 2026) on 6ix